Clinical outcomes of IDH2 ‐mutated advanced‐phase Ph‐negative myeloproliferative neoplasms treated with enasidenib-Reference-Cited by-同舟云学术

Clinical outcomes of IDH2 ‐mutated advanced‐phase Ph‐negative myeloproliferative neoplasms treated with enasidenib

Published:2020-05 Issue:1 Volume:190 Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Patel Anand A.¹^ORCID,Cahill Kirk²,Charnot‐Katsikas Angella³,Liu Hongtao¹,Gurbuxani Sandeep³,Thirman Michael¹,Kosuri Satyajit¹,Artz Andrew S.¹⁴,Larson Richard A.¹,Stock Wendy¹,Segal Jeremy³,Odenike Olatoyosi¹

Affiliation:

1. Section of Hematology/Oncology Department of Medicine University of Chicago Medicine Chicago IL USA

2. Department of Medicine University of Chicago Medicine Chicago IL USA

3. Department of Pathology University of Chicago Medicine Chicago IL USA

4. Department of Hematology and Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte CA USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16709

Reference10 articles.

1. How I treat the blast phase of Philadelphia chromosome–negative myeloproliferative neoplasms

2. Durable Remissions with Ivosidenib inIDH1-Mutated Relapsed or Refractory AML

3. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia

4. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

5. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing Outcomes of Accelerated and Blast-Phase Myeloproliferative Neoplasms;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Challenging Scenarios in the Management of Myeloproliferative Neoplasms;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era;Blood Advances;2024-06-28

4. Epigenetic dysregulation in cancers by isocitrate dehydrogenase 2 (IDH2);Advances in Protein Chemistry and Structural Biology;2024

5. IDH1/2 inhibitor monotherapy in blast‐phase myeloproliferative neoplasms: A multicentre experience;British Journal of Haematology;2023-08-03